Gabriel Tinoco

Gabriel Tinoco's research focuses on rare and difficult-to-treat cancers, particularly sarcomas (cancers of bone, muscle, and connective tissue), gastrointestinal stromal tumors, and chondrosarcoma. Much of the work involves clinical trials testing new drugs (such as olaparib, ivosidenib, vimseltinib, and emactuzumab) and investigating molecular features like IDH1/2 gene mutations to guide targeted treatment decisions. The research combines large multi-institutional clinical trials with molecular and genomic analyses to better understand tumor biology and treatment resistance.

Publication output has grown sharply over the last decade, rising from a handful of papers per year before 2020 to a large surge in 2023-2025, indicating a period of substantially increased research activity likely tied to large multicenter clinical trials.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026